

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3390330

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BASILEA PHARMACEUTICA INTERNATIONAL LTD.	07/23/2012
RECEIVING PARTY DATA	
Name:	GLAXO GROUP LIMITED
Street Address:	980 GREAT WEST ROAD
City:	BRENTFORD, MIDDLESEX
State/Country:	UNITED KINGDOM
Postal Code:	TW8 9GS
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14734249
CORRESPONDENCE DATA	
Fax Number:	(610)270-5090
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	610-270-6812
Email:	US_CIPKOP@GSK.com
Correspondent Name:	GLAXOSMITHKLINE
Address Line 1:	709 SWEDELAND ROAD
Address Line 2:	GP -UW2220
Address Line 4:	KING OF PRUSSIA, PENNSYLVANIA 19406
ATTORNEY DOCKET NUMBER:	PU65255C4
NAME OF SUBMITTER:	AUDREY BOYD
SIGNATURE:	/Audrey Boyd/
DATE SIGNED:	06/10/2015
Total Attachments: 12	
source=PU65255 US Assignment Basilea to GGL#page1.tif	
source=PU65255 US Assignment Basilea to GGL#page2.tif	
source=PU65255 US Assignment Basilea to GGL#page3.tif	
source=PU65255 US Assignment Basilea to GGL#page4.tif	
source=PU65255 US Assignment Basilea to GGL#page5.tif	

source=PU65255 US Assignment Basilea to GGL#page6.tif
source=PU65255 US Assignment Basilea to GGL#page7.tif
source=PU65255 US Assignment Basilea to GGL#page8.tif
source=PU65255 US Assignment Basilea to GGL#page9.tif
source=PU65255 US Assignment Basilea to GGL#page10.tif
source=PU65255 US Assignment Basilea to GGL#page11.tif
source=PU65255 US Assignment Basilea to GGL#page12.tif

ASSIGNMENT OF PATENTS

THIS ASSIGNMENT OF PATENTS (this "Patent Assignment") is entered into as of ²³ July 2012 by **Basilea Pharmaceutica International Ltd.**, a company incorporated under the laws of Switzerland with registered number CH-270.3.014.065-8 and having its registered office and its principal place of business at Grenzacherstrasse 487, CH-4058 Basel, Switzerland ("Assignor"), to **Glaxo Group Limited**, a company organized under the laws of the United Kingdom, and having its registered office and principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN, UK ("Assignee"). Collectively, Assignors and Assignee are referred to as the "Parties." Capitalized terms used but not otherwise defined herein shall have the definition assigned in the Asset Purchase Agreement dated as of 11 June 2012 (the "Asset Purchase Agreement") by and between Assignor and Assignee.

RECITALS

WHEREAS, pursuant to the Asset Purchase Agreement, Assignor has sold to Assignee, and Assignee has purchased from Assignor, the entire right, title and interest of Assignor and its Affiliates in and to the Toctino® Product, together with certain assets related thereto including the Acquired Patents; and

WHEREAS, in accordance with the Asset Purchase Agreement, Assignor desires to enter into this Patent Assignment to evidence the transfer to Assignee of the entire rights, title and interest of Assignor and its Affiliates in and to each of the Acquired Patents (as listed in Annex A hereof) to Assignee;

AGREEMENT

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the Parties, the Parties hereby agree as follows:

1. **Assignment.** Subject to the Licence and to any Intellectual Property and any rights and/or licences thereto, not sold or transferred to the Assignee pursuant to the Asset Purchase Agreement, Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, with effect from Completion, the entire right, title and interest of Assignor and its Affiliates in and to the Acquired Patents and all related Intellectual Property Rights including without limitation the following:

(a) all applications for the patents, all provisional applications, and all patents in the United States of America and all foreign countries granted therefore and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said applications, re-examinations, re-issues, renewals, substitutes and extensions of said patents, and all rights under the International Convention for the Protection of Industrial Property that relate specifically and exclusively to the Acquired Patents;

(b) those Acquired Patents referred to in Annex A; and

(c) the right to any take proceedings and recover damages, profits or other obtain all other remedies or recoveries in respect to past acts of infringement of the Acquired Patents or any of the other intellectual property set forth in the foregoing clauses (a) and (b) above.

035875-0001
10/1/12

2. General.

(a) This Assignment is being delivered in connection with the Asset Purchase Agreement and is subject to, and is entitled to the benefits in respect of, the Asset Purchase Agreement. Assignor acknowledges and agrees that the Acquired Patents are to be held and enjoyed by Assignee, its successors and assigns, for their own use as fully and entirely to the same extent as the Acquired Patents would have been held and enjoyed by Assignor had this assignment not been made.

(b) Assignor hereby agrees to cooperate with Assignee as reasonably necessary to give full effect to and perfect the rights of Assignee in the Acquired Patents. Assignor hereby covenants and agrees to and with Assignee, its successors, legal representatives and assigns that Assignor will, at the expense of Assignee, sign and deliver all certificates, instruments, papers and documents, make all lawful affidavits, testimonies, declarations and oaths, and do all acts necessary or required to be done for the recordation of this assignment of the Acquired Patents to Assignee. Assignee may record this Patent Assignment in any and all patent offices around the world, including but not limited to, the United States Patent and Trademark Office.

(c) Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States to issue to, and record in the name of, Assignee, any and all Letters Patent of the United States arising from such Transferred Patents for the use and behalf of Assignee, its successors, legal representatives, and assigns.

(d) This Assignment shall be binding upon and inure to the benefit of Assignors and Assignee and to their respective successors and assigns.

(e) This Assignment may be executed in 2 (two) or more counterparts, each of which shall be deemed an original and all of which shall constitute one instrument.

(f) This Assignment is executed for purpose of evidencing and confirming the transfer of the Acquired Patents from Assignor to Assignee as provided in the Asset Purchase Agreement. Nothing contained in this Assignment is intended to modify any of the provisions of the Asset Purchase Agreement as they relate to the Acquired Patents, including any of the representations, warranties, covenants or indemnities set forth in the Asset Purchase Agreement. In the event of any conflict between this Assignment and the Asset Purchase Agreement, the Asset Purchase Agreement controls.

(g) Nothing in this Assignment, express or implied, is intended to confer upon any third party (other than a permitted successor or assign of a party hereto) any rights, remedies, obligations or liabilities.

(h) This Assignment, the Asset Purchase Agreement and the other Transaction Documents constitute the entire understanding of the parties, and supersede and pre-empt all prior oral or written understandings, discussions and agreements with respect to the subject matter hereof. This Assignment or any provision hereof cannot be amended, changed or waived except in a writing signed by each party hereto.

3. Power of Attorney. Effective as of the date of this agreement, Assignor hereby constitutes and appoints Assignee and its successors, assigns and agents, as Assignor's true and lawful attorney-in-fact, with full power of substitution, in the name of Assignor and its successors and assigns, and for the benefit of Assignor: (i) to demand and receive from time to time any and all of the Acquired Patents and to give and make receipts, releases and endorsements for and in respect of the same or any part thereof; (ii) to make any and all necessary or appropriate filings with any applicable Governmental Entity in order to evidence the transfer of the Acquired Patents to Assignee; (iii) to institute, prosecute, compromise and settle any and all actions or proceedings at law, in equity or otherwise as Assignee may deem necessary or



appropriate in order to assert or enforce any claim, right or title of any kind in, to or under any of the Acquired Patents; (iv) to defend, compromise or settle any and all actions or proceedings with respect to any of the Acquired Patents; and (v) to do all such acts and things with respect to the matters set forth in the preceding clauses (i) through (v) as Assignee shall deem reasonably necessary or appropriate. Assignor hereby agrees that the appointment made pursuant to this Section 3 and the powers hereby granted are coupled with an interest and are and shall be irrevocable.

4. Assignee Has No Duty. The powers conferred on Assignee hereunder are solely to protect its interest in the Acquired Patents and shall not impose any duty on it to exercise any such powers.

5. Governing law and submission to jurisdiction. The construction, validity and performance of this Assignment and all non-contractual obligations arising from or connected with this Assignment shall be governed by the laws of England.

Any dispute between the parties arising out of or in relation to this Assignment, including in respect of the validity, invalidity, breach or termination thereof, shall exclusively be settled in the following manner, provided however, if any statute of limitations on any dispute would toll during the dispute resolution process as set forth below, the party raising such dispute may proceed in filing a Notice of Arbitration as set forth in 5(c) below:

(a) such dispute shall be referred to the Chief Executive Officer of the Seller and the President of Stiefel Laboratories, Inc., each of whom shall work in good faith to resolve the relevant dispute. Such officers shall meet, either in person or by telephonic conference, within 30 (thirty) calendar days of the delivery of notice by a party to the other of a dispute;

(b) to the extent that such dispute is not resolved pursuant to clause 5(a) above, such dispute may be submitted to non-binding mediation in accordance with the Swiss Rules of Commercial Mediation of the Swiss Chambers of Commerce in force on the date when the Notice of Mediation is submitted in accordance with such rules;

(c) To the extent that such dispute is not resolved in the course of the non-binding mediation pursuant to clause 5(b) above, the dispute shall be settled by arbitration in accordance with the Swiss Rules of International Arbitration of the Swiss Chambers of Commerce in force on the date when the Notice of Arbitration is submitted in accordance with such rules. The number of arbitrators shall be 3 (three). The seat of the arbitration shall be in Zurich in Switzerland. The proceedings shall be conducted in English.

(Signature page follows)



IN WITNESS WHEREOF, the Parties hereto have executed this Assignment as of the date first written above.

SIGNED by Anthony Man, Chief Executive Officer
duly authorised for and on behalf
of Basilea Pharmaceutica International Ltd.

)
)
) 

SIGNED by Ronald Scott, Chief Operating Officer
duly authorised for and on behalf
of Basilea Pharmaceutica International Ltd.


)
)
) 

SIGNED by
duly authorised for and on behalf
of Glaxo Group Limited

)
)
)



IN WITNESS WHEREOF, the Parties hereto have executed this Assignment as of the date first written above.

<p>BASILEA PHARMACEUTICA INTERNATIONAL, LTD.</p> <p>By: _____</p> <p>Name: _____</p> <p>Title: _____</p>	<p>GLAXO GROUP LIMITED</p> <p>By: </p> <p>Name: Paul Williamson Authorized Signatory For and on behalf of The Wellcome Foundation Limited Corporate Director</p> <p>Title: _____</p>
<p>BASILEA PHARMACEUTICA INTERNATIONAL, LTD.</p> <p>By: _____</p> <p>Name: _____</p> <p>Title: _____</p>	

Execution Version

Annex A
Acquired Patents

0.01 - List
1 2 3 4
A B C D

2011104 Status Order Patent Orders 2011104_P04.0178 / All Families

STATUS Status of Patent Registrations as of 31 October 2011 All Patent Families

Page 1

Patent Number	Family Code	Family	Title	Country Code	State	Application No.	Application Date	Patent No.	Patent Date	Owner
BAL4078	23001	US2	New Formulation for reticose containing soft gelatin capsules	US	Final	1,127,327	12/22/2009	1,127,327	05/05/2011	Pharm. Pharmabonded AG
BAL4078	23001	US2	New Formulation for reticose containing soft gelatin capsules	US	Provisional	11,202,429	04/04/2009	11,202,429	04/04/2009	Pharm. Pharmabonded AG
BAL4078	23002	23002	Method for varying cross link densities with 5-oxo-reticose and other polymers	US	Provisional	11,202,429	04/04/2009	11,202,429	04/04/2009	Pharm. Pharmabonded AG
BAL4078	23002	23002	Method for varying cross link densities with 5-oxo-reticose and other polymers	US	Final	1,127,327	12/22/2009	1,127,327	05/05/2011	Pharm. Pharmabonded AG

Classified Pending in program 79
 Not Pending in program 0
 Abandoned 0



BAL4079 Status of Patent Registrations as of 31 October 2011: All Patent Families

Basilea Patent No.	Family No.	Title	Country Code	Status	Application No.	Application Date	Parent No.	Grant Date	Expiry Date	Owner
BAL4079	11271	Pharmaceutical compositions	AU	Granted	31861/93	18.01.1993	65784	30.07.1996	18.01.2013	Basilea Pharmaceutica AG
BAL4079	11271	Pharmaceutical compositions	IL	Granted	104450	20.01.1993	104450	07.01.1999	20.01.2013	Basilea Pharmaceutica AG
BAL4079	11271	Pharmaceutical Compositions	MX	Granted	930270	20.01.1993	187885	27.01.1998	20.01.2013	Basilea Pharmaceutica AG
BAL4079	11271	Pharmaceutical compositions	NZ	Granted	245686	15.01.1993	245686	12.09.1995	15.01.2013	Basilea Pharmaceutica AG
BAL4079	11271	Pharmaceutical compositions	PH	Granted	45577	19.01.1993	31621	12.01.1999	12.01.2016	Basilea Pharmaceutica AG
BAL4079	11271	Pharmaceutical compositions	ZA	Granted	93/0286	15.01.1993	93/0286	29.09.1993	15.01.2013	Basilea Pharmaceutica AG
BAL4079	11271 H01	Pharmaceutical compositions containing 9-cis retinoic acid	HU	Granted	P/P00236	19.06.1995	211.167	31.08.1995	15.01.2013	Basilea Pharmaceutica AG
BAL4079	11468	Prevention and treatment of premalignant epithelial lesions and malignant tumors of epithelial origin	US	Abandoned	07/823741	22.01.1992				F. Hoffmann-La Roche AG
BAL4079	11468 US1	Prevention and treatment of premalignant epithelial lesions and malignant tumors of epithelial origin	US	Granted	08/201493	24.02.1994	5428071	27.06.1995	27.06.2012	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	AT	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	AU	Granted	94356/98	18.08.1998	739440	24.01.2002	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	BE	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	BR	Pending	P9811989-3	18.08.1998				Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	CA	Granted	2.301.907	18.08.1998	2.301.907	10.02.2009	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	CH	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	CN	Granted	CO1007020/01	05.02.2010	CO1007020/01	31.01.2011	17.08.2023	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	DE	Granted	98947437.4	18.08.1998	1.007.020	04.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	DK	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	EP	Abandoned	97114651.9	23.08.1997				F. HOFFMANN-LA ROCHE AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	ES	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	FI	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	FR	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	GB	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	GR	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	IE	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	IT	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	JP	Granted	2000-507359	18.08.1998	3522220	20.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	KR	Granted	2000-7001813	18.08.1998	10-0596280	26.06.2006	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	LU	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	MX	Granted	1803	18.08.1998	1230485	09.09.2005	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	NL	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	NO	Granted	200000870	18.08.1998	3271.41	04.05.2009	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	NZ	Granted	502812	18.08.1998	502812	09.09.2002	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	PT	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	RU	Granted	2000.107.124	18.08.1998	2.238.083	15.03.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	SE	Granted	98947437.4	18.08.1998	1.007.020	11.02.2004	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	TR	Granted	00/0488	18.08.1998	TR.2000.00488.B	21.02.2006	18.08.2018	Basilea Pharmaceutica AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	US	Granted	09/485943	18.08.1998	6.589.989	08.07.2003	18.08.2018	F. HOFFMANN-LA ROCHE AG
BAL4079	20157	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	WO	Abandoned	PCT/EP98/05236	18.08.1998				F. HOFFMANN-LA ROCHE AG
BAL4079	20157 EP1	TREATMENT OF CELL-MEDIATED IMMUNE DISEASES	EP	Abandoned	98947437.4	18.08.1998	1.007.020	11.02.2004		Basilea Pharmaceutica AG

BAL4079 Status of Patent Registrations as of 31 October 2011: All Patent Families

Basilea Project	Family No.	Family No.	Title	Country Code	Status	Application No.	Application Date	Patent No.	Grant Date	Expiry Date	Owner
BAL4079	20157	20157 US1	Treatment of cell-mediated immune diseases	US	Abandoned	10/459,273	11.06.2003				Basilea Pharmaceutica AG
BAL4079	20157	US2	Treatment of cell-mediated immune diseases	US	Pending	11/432,955	12.05.2006				Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	AT	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	AU	Granted	2004290494	28.10.2004	2004290494	02.10.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	BE	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	BG	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	BR	Pending	PI0415634-0	28.10.2004				Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	CA	Granted	2 541 292	28.10.2004	2 541 292	14.09.2010	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	CH	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	CN	Granted	200480032140.1	28.10.2004	ZL2004800321	24.03.2010	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	CY	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	CZ	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	DE	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	DK	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	EE	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	EP	Abandoned	03405788.5	03.11.2003				Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	ES	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	FR	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	GB	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	GR	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	HU	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	IE	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	IT	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	JP	Granted	2006-537142	28.10.2004	4553827	23.07.2010	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	KR	Granted	2006-7007881	28.10.2004	856562	28.08.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	LU	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	MC	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	MX	Granted	PA/2006/00382	28.10.2004	257879	12.06.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	NL	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	NO	Pending	2006 1890	28.10.2004				Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	NZ	Granted	546258	28.10.2004	546258	08.04.2010	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	PL	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	PT	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	RO	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	RU	Granted	2006 119 326	28.10.2004	2 344 810	11.08.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	SE	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	SI	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	SK	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	TR	Granted	04790978.3	28.10.2004	1 680 096	16.04.2008	28.10.2024	Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	US	Abandoned	10/958,704	05.10.2004				Basilea Pharmaceutica AG
BAL4079	22001	22001	New formulation for rebind-containing soft gelatin capsules	WO	Abandoned	PCT/EP2004/0122	28.10.2004				Basilea Pharmaceutica AG
BAL4079	22001	EP1	New formulation for rebind-containing soft gelatin capsules	EP	Abandoned	04790978.3	28.10.2004	1 680 096	16.04.2008		Basilea Pharmaceutica AG

Handwritten initials: "SFC"

BAL4079 Status of Patent Registrations as of 31 October 2011: All Patent Families

Basilea Project	Family	Family No.	Trade	Country Code	Status	Application No.	Application Date	Patent No.	Grant Date	Expiry Date	Owner
		87									
BAL4079	22001	22001 US1	New formulation for rethroid-containing soft gelatin capsules	US	Pending	12/640,325	17.12.2009				Basilea Pharmaceutica AG
BAL4079	22001	22001 US2	New formulation for rethroid-containing soft gelatin capsules	US	Pending	13/086,479	14.04.2011				Basilea Pharmaceutica AG
BAL4079	22042	22042	Method for treating chronic handderma with 9- <i>cis</i> -retinoic acid and Immunomodulators	EP	Pending	1117464.5	20.07.2011				Basilea Pharmaceutica AG

Granted 70
 Pending 7
 FIP (Filing in progress) 0
 Abandoned 9
 86

72 70

45